ArticleGland surgery2024
Discordance in biomarker expression between primary breast cancers and loco-regional recurrences: a comprehensive analysis of 112 cases.
Article in Gland surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is a complex disease encompassing multiple phenotypic and genetic subtypes. The biomarker status of primary and recurrent lesions may be dissimilar, and changes in biomarker status may inform clinical decision-making. The expression of biomarkers between primary breast cancers and loco-regional recurrences lacked large sample studies. This study aimed to investigate the discordance in the status of specific biomarkers between primary breast cancers and loco-regional recurrences, while also exploring the associated clinical and pathological characteristics of the affected patients. Methods: A retrospective review was conducted on the medical records of 112 female patients with a confirmed pathological diagnosis of breast cancer who experienced loco-regional recurrence between July 2005 and March 2018 at Peking Union Medical College Hospital. Comprehensive data regarding primary and recurrent tumor characteristics, surgical interventions, history of systemic therapy, presence and management of loco-regional recurrences, as well as disease-free survival (DFS) and overall survival (OS), were systematically recorded and subsequently subjected to comparative analysis. Results: The study revealed disparities in the expression of individual biomarkers between primary breast cancers and loco-regional recurrences, with discordance rates exhibiting variation across breast cancer subtypes. Specifically, the overall discordance rates were as follows: 9.8% for estrogen receptor (ER) expression, 15.2% for PR expression, 7.6% for human epidermal growth factor receptor-2 (HER2) expression, and 20.6% for the Ki-67 index (21 out of 102 cases). Luminal A tumors exhibited the highest discordance rate at 81.8%, while triple negative (TN) tumors displayed the lowest at 9.1%. Furthermore, a statistically significant association was identified between DFS and the subtype of primary breast cancer (P=0.002). Conclusions: The study shows that there exists discordance in the expression of individual biomarkers between primary breast cancers and loco-regional recurrences. The discordance rate was found to be highest among luminal A tumors and lowest for TN tumors. Additionally, patients with HER2 and TN primary breast tumors exhibited the shortest DFS. Based on these findings, the study recommends the implementation of biomarker testing for recurrent breast cancers as a valuable strategy to inform and guide decisions regarding the selection of rescue chemotherapy, endocrine therapy, and targeted therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.